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The design and synthesis of functional chemical derivatives of small organic molecules is usually a key step for the intricate 
production of a variety of bioconjugates. In this respect, the derivatization site at which the spacer arm is introduced in 
immunizing conjugates constitutes a highly critical parameter for the generation of high-affinity and selective antibodies. 
However, due to the usual complexity of the required synthetic procedures, the appropriate comparison of alternative tethering 10 
positions has often been neglected. In the present study, meticulous strategies were followed to prepare synthetic derivatives of 
pyraclostrobin with the same linkers located at diverse rationally-chosen sites. Activity appraisal of antibodies and 
bioconjugates was carried out by bidimensional competitive direct and indirect immunoassays, and a superior performance of 
two of the three synthesized haptens was found. Finally, a detailed analysis of the conformations of the target molecule and the 
synthesized haptens in aqueous solution was done using computer assisted molecular modeling techniques. This study suggested 15 
that the lower titers and affinities of one set of antibodies are most probably due to conformational effects of the spacer arm in 
the immunizing bioconjugate. 
 
Introduction 
The production of high-affinity and selective binders to small 20 
organic molecules is a biotechnological research field of huge 
importance for such diverse disciplines as drug discovery, 
clinical diagnostics, food safety, and environmental 
monitoring. Antibodies are the paradigm of binding proteins 
due to their exquisite molecular recognition ability. Long ago, 25 
Nobel-prize winner Karl Landsteiner was the first to discover 
that low molecular weight compounds become immunogenic 
only after association with a carrier protein, coining the term 
hapten for these substances.1 Because small organic molecules 
usually lack ready-to-activate chemical groups for protein 30 
conjugation, the generation of high-quality antibodies 
exhibiting the desired ligand-binding features strongly relies 
on the synthesis of suitable functional derivatives of the target 
analyte. Such synthetic derivatives should closely mimic the 
target ligand, maximizing the steric, hydrophobic, and 35 
electronic similarity to the parent molecule. Most commonly, 
synthetic haptens incorporate a spacer arm to better display 
the molecule, thus facilitating its recognition by the receptor, 
despite the fact that direct coupling of the analyte to the 
carrier protein, when possible, has occasionally been 40 
employed.2 Although the physico-chemical characteristics of 
the analyte determine the optimum properties of the spacer 
arm for hapten conjugation, linear aliphatic bridges are known 
to cause negligible interferences over the production of 
antibodies if an optimum length of two to six carbon atoms is 45 
maintained.3 Nevertheless, a critical parameter for the 
production of antibodies is, most noteworthy, the 
derivatization site; that is, the position at which the spacer 
arm is attached to the molecule. The linker position will mold 
the final conformation of the conjugate and therefore, it will 50 
settle the specific moieties that will be accessible for binding. 
Even if these general considerations are simple and 
qualitative, they have generally been extremely useful – in 
combination with rational and judicious chemical examination 
of the target molecule by qualified chemists – for the 55 
synthesis of appropriate haptens and bioconjugates applied to 
the production of antibodies with the desired binding 
properties. Lately, molecular modeling techniques are being  
 
Figure 1 Structure of PY and the three synthetic haptens. 60 
increasingly used as complementary tools to assist researchers 
in, for instance, the prediction of the best hapten structures for 
immunoconjugate preparation or the interpretation of 
experimental results regarding affinity or selectivity of 
receptors.4 65 
Strobilurins are a new class of synthetic biocides displaying 
outstanding properties and a new mode of action, so the 
introduction of the first strobilurin fungicides in 1996 meant a 
significant contribution to the fight against fungal diseases.5 
As part of an ongoing project aimed at obtaining high-affinity 70 
antibodies and developing immunochemical methods to 
selectively detect the most relevant chemicals of the 
strobilurin family of pesticides, we chose pyraclostrobin (PY) 
as a model analyte to ascertain the influence of the spacer arm 
attachment site on the affinity of the derived antibodies. PY is 75 
considered as a second generation strobilurin fungicide, and it 
is composed of a methoxycarbamate toxophore moiety, an 
aryl bridge, and a characteristic two-ring system (Figure 1). In 
this article, we describe the synthesis of PY derivatives with 
the spacer arm located at different sites of the molecule. To 80 
rigorously compare the suitability of these synthetic haptens 
for inducing the formation of high-affinity antibodies, a 
homogenous linker of comparable length and composition was 
used for coupling to the same carrier protein. Very few 
examples have been found in the literature in which the same 85 
spacer arm was used to prepare several functionalized haptens 
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Scheme 1 Synthesis of hapten PYa6. 
 
through different derivatization sites in order to find the 
optimum orientation of the molecule.6 Antisera, representing 5 
the unbiased whole-response of the animal immune system, 
were chosen as the source of antibodies. The affinity and 
selectivity of the generated reagents were evaluated by 
competitive enzyme-linked immunosorbent assay (cELISA) 
using the conjugate-coated indirect and the antibody-coated 10 
direct formats. Finally, our results were assessed with 
computer-generated molecular models of the target molecule 
and the synthesized haptens. 
 
Results and discussion 15 
Chemistry 
After a rational examination of the planar structure of PY 
(Figure 1), three key positions for the introduction of the 
spacer arm and analyte functionalization became readily 
apparent: the methoxycarbamate toxophore moiety, the arylic 20 
bridge, and the chlorophenyl moiety. Accordingly, three PY 
analogues, namely, PYo5, PYa6, and PYs5 (Figure 1), were 
proposed as haptens for the production of high-affinity 
antibodies. All three structures maintained the complete 
hydrocarbon skeleton and the most characteristic functional 25 
groups of the analyte, incorporating the hydrocarbon spacer 
arm at positions where minimum modifications of steric and 
electronic properties of the molecule were expected. 
Moreover, the length and composition of the spacer arms were 
nearly identical in all three haptens. The synthesis of haptens 30 
PYa6 and PYs5 is herein reported for the first time, whereas 
the preparation of hapten PYo5 was previously described by 
our group in a study dealing with the influence of the spacer 
arm length on antibody production.7 In hapten PYa6, the 
spacer arm is directly attached to the aryl ring that contains 35 
the methoxycarbamate group through a single carbon-carbon 
bond, while in hapten PYs5 the hydrocarbon spacer chain is 
bonded to the other (opposite) aryl group through a sulphur 
bridge that replaced the chlorine atom of PY. A preliminary 
examination of the synthetic routes required for the 40 
preparation of haptens PYa6 and PYs5 evidenced that rather 
laborious and multi-step schemes would be required to 
prepare these analogues. Initial attempts to introduce the 
spacer arm at the required positions directly on PY failed, so 
haptens had to be finally prepared by total synthesis starting 45 
from ready available materials. We used an adaptation of the 
strategy previously reported for the preparation of PY8 and 
related compounds,9 which involved, for such cases, the 
alkylation of a 1-aryl-1H-pyrazol-3-ol with a methyl 
2-(bromomethyl)-phenyl(methoxy)carbamate as the key 50 
synthetic step for the elaboration of the characteristic PY 
framework. 
The synthesis of hapten PYa6 (11) began with the iodination 
reaction of methyl methoxy(o-tolyl)carbamate (1) using iodine 
and silver sulphate in AcOH (Scheme 1). This reaction is 55 
highly efficient and regioselective, affording exclusively the 
4-iodo compound 2. Radical benzylic bromination of 2 with 
N-bromosuccinimide and azobisisobutyronitrile as the initiator 
under standard thermal conditions afforded a very low yield of 
the desired benzylic bromide, a result that contrasted with that 60 
obtained in the bromination reaction of the non iodinated 
analogue (see below). However, an acceptable yield of benzyl 
bromide 3 was obtained when the free radical bromination of 
iodide 2 was undertaken with bromine under radiation-
induced conditions at room temperature. Under these 65 
conditions, the reaction afforded a mixture of bromide 3 and 
unreacted starting material, together with minor amounts of 
the corresponding benzylic dibrominated derivative, which 
could not be separated by conventional chromatographic 
methods, so it was used as such in the following step. Thus, 70 
the expected benzyl ether 7 was obtained in excellent yield 
from the reaction of this mixture with 
1-(4-chlorophenyl)-1H-pyrazol-3-ol (6), readily prepared 
according to a literature procedure10 by reaction of 
(4-chlorophenyl)hydrazine hydrochloride (4) with methyl 75 
acrylate and oxidation of the resulting pyrazolidinone 5 with 
oxygen and catalytic CuCl in about 57% overall yield. Once 
the tricyclic ring system present in PY had been prepared, the 
synthesis of hapten PYa6 was completed via substitution of 
the iodine atom in 7 by the C6 hydrocarbon chain using 80 
palladium catalyzed coupling methodology. Thus, 
Sonogashira cross-coupling of iodide 7 with alkyne tert-butyl 
ester 8 under standard conditions afforded the acetylenic 
compound 9, which was hydrogenated using Wilkinson's 
catalyst to give compound 10 in 90% overall yield for the two 85 
steps. The synthesis of hapten PY6a was completed by 
hydrolysis of the tert-butyl ester group of 10, which took 
place in nearly quantitative yield by treatment with 
trifluoroacetic acid at 0 °C.  
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Scheme 2 Synthesis of hapten PYs5. 
 
The synthesis of hapten PYs5 (20) began with the 
preparation of 1-(4-iodophenyl)-1H-pyrazol-3-ol (14) 5 
(Scheme 2), which was obtained from 
(4-iodophenyl)hydrazine (12) via a two step process involving 
condensation with tert-butyl acrylate catalyzed by potassium 
tert-butoxide and subsequent oxidation of the obtained 
dihydropyrazolone 13 with air catalyzed by CuCl. The 10 
pyrazolol 14 was obtained with an overall yield of about 60%. 
Replacement of the iodine atom in 14 by the alkyl sulfide 
chain was efficiently carried out by Cu-catalyzed 
cross-coupling reaction of the aryl iodide with the thiol 16, 
which was in turn prepared from tert-butyl 15 
5-bromopentanoate (15) and thiourea in very high yield via 
formation of the thiouronium salt followed by cleavage with 
sodium pyrosulfite.11 The synthesis of the whole framework 
of hapten PYs5 was completed by alkylation of the pyrazolol 
moiety of 14 with the known methyl 20 
2-(bromomethyl)phenyl(methoxy)carbamate (18) in a similar 
way to that described above for the other hapten. Under these 
conditions, the alkylation reaction afforded the tert-butyl ester 
19 in an excellent 89% yield. Finally, acid hydrolysis of the 
tert-butyl ester group of 19 by trifluoroacetic acid treatment 25 
gave the desired hapten PYs5 (20) with also an excellent 
yield.  
Bioconjugates and antibodies 
The hapten density of the immunogenic conjugates is a 
fundamental parameter that determines the titer and the 30 
affinity of the generated antibodies. Hapten’s carboxyl groups 
were activated for coupling to the ε-amine residues of the 
carrier proteins by standard procedures (see experimental 
part). The hapten-to-protein molar ratios (MR) of the three 
bioconjugates to bovine serum albumin (BSA) were 35 
determined by differential absorbance measurements and 
MALDI-TOF-MS. Similar values were retrieved by both 
analytical methods (Table 1) as also observed by other 
authors,12 except for the MR of BSA−PYa6 when calculated 
by differential absorption, which seemed to be overestimated. 40 
Anyhow, equivalent MRs for the three immunogens were 
found as required for a proper comparison of the immune 
response. The observed MRs of our BSA conjugates were in 
the same range as the optimum MRs for immunogenic 
conjugates determined by Boro et al.13 using the same carrier 45 
protein. For assay conjugates, carrier proteins different to the 
immunogen are demanded, so ovalbumin (OVA) and 
horseradish peroxidase (HRP) were employed. Considering 
the calculated MRs of these conjugates, it could also be seen 
that both of the PYa6 assay conjugates were slightly higher 50 
than those of the other haptens, as it happened with the 
BSA−PYa6 conjugate. Unfortunately, the MRs of OVA 
conjugates could not be determined by MALDI-TOF-MS, and 
the same mass spectra were obtained for the unconjugated and 
the conjugated HRP samples, probably due to the low density 55 
of hapten molecules in the conjugates. In any case, all assay 
(HRP and OVA) conjugates behaved correctly in the cELISA 
at usual concentrations, demonstrating that they carried 
sufficient hapten molecules for adequate assay performance.  
Table 2 Assay parameters achieved with homologous conjugates in the two cELISA formats 
  Indirect cELISAa  Direct cELISAb 
Antiserum  
Antiserum 
dilution (×103) Amax IC50  
[Tracer] 
(ng/mL) Amax IC50 
rPYo5#1   30 1.40 ± 0.29  4.9 ± 2.0   300   0.94 ± 0.09 10.2 ± 0.9  
rPYo5#2   30 1.24 ± 0.14  6.8 ± 1.8   100   0.93 ± 0.26 8.4 ± 2.6  
rPYa6#1     3 0.90 ± 0.25  14.4 ± 4.5   300   0.87 ± 0.01            > 100  
rPYa6#2   10 c 1.19 ± 0.01  43.0 ± 5.9   300   0.46 ± 0.07d             > 100  
rPYs5#1   10 0.92 ± 0.33  5.0 ± 1.0   30   1.38 ± 0.18 6.9 ± 1.1  
rPYs5#2   10 0.85 ± 0.09  1.7 ± 0.8   10   0.86 ± 0.12 1.5 ± 0.3  
a Coating with homologous conjugate at 100 ng/mL.  b Antibody dilution was 1/3000. c Assay obtained with 1.0 µg/mL homologous conjugate. 
d Amax above 0.5 could not be reached. 
Table 1 Molar ratios of the different bioconjugatesa 
  BSA  OVA HRP 
Hapten  Abs.b MALDIc  Abs. Abs. 
PYo5  19 12  5 4 
PYa6  25 15  8 6 
PYs5  17 17  6 3 
a Hapten densities were calculated as moles of hapten per mole of protein. 
b Hapten densities retrieved by differential absorbance measurements. c Hapten 
densities calculated by MALDI-TOF-MS. 
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Six rabbits were immunized and blood samples were 
collected after the third immunization. Titers of the two 
BSA−PYa6 immunized animals were approximately 104, 
whereas those of animals immunized with BSA−PYs5 and 
BSA−PYo5 were around 10 and 50 times higher, respectively. 5 
The titers did not improve after the fourth immunization, and 
consequently the animals were exsanguinated. Finally, two 
antisera were generated from each immunogen: antisera 
rPYa6#1 and #2 from immunogen BSA−PYa6, antisera 
rPYo5#1 and #2 from immunogen BSA−PYo5, and antisera 10 
rPYs5#1 and #2 from immunogen BSA−PYs5. 
The influence of the derivatization site of assay conjugates 
was evaluated for the two most common cELISA formats. 
Depending on the ELISA format, OVA−hapten conjugates 
were used as passive immobilized competitive reagent for 15 
indirect assays whereas HRP−hapten conjugates were 
employed as enzyme tracer conjugates in direct assays. The 
binding properties of the generated polyclonal antibodies were 
initially evaluated as the IC50 value of the inhibition curve that 
was retrieved in homologous competitive assays with PY as 20 
free analyte (Table 2). Standard curves were run using an 
array of concentrations of the antibody and the assay 
conjugate, so that a family of inhibition curves was generated; 
one curve for each combination of immunoreagents. This 
approach enabled a simultaneous, and therefore comparable, 25 
determination of the IC50 values under different experimental 
conditions, so information about antibody affinity was rapidly 
acquired without a previous titration assay. We found that, in 
the conjugate-coated indirect format, the antisera generally 
performed better (lower IC50 values) when OVA−hapten 30 
conjugates were employed at 0.1 µg/mL (Table 2). Under 
optimum conditions for each combination of immunoreagents, 
antibodies derived from haptens PYo5 and PYs5 recognized 
PY with a similar affinity, with antiserum rPYs5#2 displaying 
the lowest IC50 value (1.7 nM). On the contrary, antisera from 35 
hapten PYa6 showed lower affinity. These divergent results 
were even more evident in the antibody-coated direct format, 
in which antibodies from hapten PYa6 clearly did not perform 
as advantageously as the antibodies derived from the two 
other haptens. Figure 2 shows the standard curve for the 40 
optimized assay in the antibody-coated direct cELISA format 
resulting from the combination of antiserum rPYs5#2 with its 
homologous tracer HRP−PYs5. This assay afforded a theoretical 
limit of detection of 0.13 nM (50 ng/L). 
The antibody apparent affinity that results from the 45 
calculated IC50 values may be influenced by the hapten 
conjugate that is used for solid phase coating in indirect 
assays or that is coupled to the enzyme in direct assays. 
Therefore, cELISAs were also undertaken with heterologous 
conjugates for each antiserum (Table 3). Both, PYs5-type 50 
antisera and PYo5-type antisera recognized the coating 
OVA−PYa6 conjugate. However, very modest improvements 
of the IC50 values, if any, were observed with these 
heterologous assays as compared with the corresponding 
homologous combinations. On the contrary, PYa6-type 55 
antisera did increase their apparent affinity to PY with 
heterologous OVA conjugates. As expected, the antibody-
coated direct format was much more demanding about using 
heterologous haptens because no binding (or not enough 
binding) to the tracer conjugate was observed in most cases. 60 
As a matter of fact, heterologous direct assays could only be 
developed with PYo5-derived antibodies in combination with 
the enzyme tracer HRP−PYa6 (Table 3). Interestingly, 
antiserum rPYs5#2, displaying the highest affinity to PY in 
the homologous assays, was the only antibody unable to 65 
recognize any heterologous haptens. Overall, the same 
conclusion was deduced from homologous and heterologous 
assays; that is, PYo5 and PYs5 haptens performed better as 
immunogens than hapten PYa6.  
 70 
Figure 2 Standard curve for the optimized direct cELISA using antiserum 
rPYs5#2 and the homologous tracer. The Amax value was 0.84. Values are 
the mean of three independent experiments. 
For selectivity studies, competitive assays were run in the 
conjugate-coated indirect format with all of the antibodies at 75 
the selected immunoreagent concentrations to give Amax 
values between 1.0 and 1.5 and using PY and other analytes as 
competitors. Homologous conjugates were used in each case 
at 0.1 µg/mL, except for antiserum rPYa6#2, for which the 
OVA−PYa6 conjugate was used at 1.0 µg/mL. Remarkably, 80 
no member of the strobilurin family other than PY was 
recognized by any of the antisera, disregarding the 
derivatization site of the immunogen. All of the strobilurin 
fungicides (azoxystrobin, picoxystrobin, kresoxim-methyl, 
trifloxystrobin, dimoxystrobin, fluoxastrobin, and 85 
orysastrobin) were assayed up to 1 µM. The selectivity of the 
six antisera towards other fungicides like boscalid, 
famoxadone, fenamidone, or cyazofamid, which are 
Table 3 Assay parameters achieved with heterologous conjugates in the two cELISA formatsa 
                  Indirect cELISAb  Direct cELISAc 
Antiserum 
OVA 
conjugate 
Antiserum 
dilution (×103) Amax IC50 (nM) 
HRP 
conjugate 
[Tracer] 
(ng/mL) Amax IC50 (nM) 
rPYo5#1 PYa6 30 1.23 ± 0.22 2.4 ± 0.3 PYa6 300 1.01 ± 0.10   6.3 ± 0.5 
rPYo5#2 PYa6 10 1.57 ± 0.14 6.2 ± 1.4 PYa6 300 0.91 ± 0.22 22.2 ± 6.1 
rPYa6#1   PYo5d   3 1.01 ± 0.32 7.5 ± 4.0     
rPYa6#2 PYo5 30 0.95 ± 0.09 15.4 ± 1.9     
rPYs5#1 PYa6   3 1.28 ± 0.32 4.2 ± 0.9     
rPYs5#2         
a Only results of those immunoreagent combinations that afforded Amax values over 0.5 are given. b Coating conjugate was at 1.0 µg/mL. c Antibody 
dilution was 1/3000. d Coating conjugate concentration was 0.1 µg/mL. 
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commonly formulated together with PY, was also 
investigated. Again, none of the antisera bound any of these 
compounds. 
Computational analysis 
PY is a medium-sized hapten with a very high degree of 5 
conformational flexibility due to the large number of bonds 
that display free rotation (see Table 1SI in the ESI†). As a 
previous step to study the molecular properties of the 
functionalized haptens, the lowest-energy conformers of PY in 
water were determined using computer assisted techniques. 10 
This molecular search resulted in a large amount of 
conformers (see Figure 1SI), which were processed and 
analyzed as described in the experimental part (see the section 
for determination of minimum-energy conformations). 
Figure 3 depicts the optimized geometry (PM3-H2O) of the 15 
conformer that displayed the lowest energy value (refer to 
Figure 2SI for the geometries of the other minimum-energy 
conformers, their classification and selection). Interestingly, 
the PY molecule, like the natural strobilurin A and several of 
its analogues,14 does not adopt an extended geometry in 20 
solution. All minimum-energy conformations were 
characterized by two planar moieties – one plane was formed 
by the chlorophenyl and pyrazolyloxy moieties and the other 
plane was formed by the ortho-substituted benzene ring – with 
an angle between them varying from 100 to 120 degrees. A 25 
more accurate representation of the true shape of PY is given 
by the electron density isosurface showed in the bottom of 
Figure 3 which also reflects the electrostatic potential at every 
point on the surface. Electronic distribution and geometry are 
objective criteria to assist hapten design and interpret 30 
antibody behavior. Our experimental data clearly evidenced 
the advantage of haptens PYo5 and PYs5 over PYa6 with 
regard to the production of anti-PY antibodies (Tables 2 and 
3). Sanvicens et al.15 found that the best antibody for  
Figure 3 Two views of the lowest energy conformer found for PY 35 
observed from two different points of view. In the upper structure, the 
elements are represented in the following manner: carbon, grey; 
oxygen, red; nitrogen, blue; and chlorine, green. The lower structure 
represents the electron density surface colored by electrostatic 
potential of a different view of the most stable conformation of PY. 40 
The energy values [in atomic units (au)] at each color interface are: 
white−red, +0.09 au; red−yellow, +0.02 au; yellow−green, +0.01 au; 
green−light blue, 0.00 au; light blue−dark blue, −0.01 au; dark 
blue−pink, −0.03 au; pink−violet, −0.06 au; where 1 au = 627.503 
kcal/mol. 45 
trichloroanisol was obtained with an immunizing hapten in 
which the spacer arm had been introduced by substitution of a 
C−Cl bond by a C−C linkage – which made the aromatic 
carbon atom much more positive. In contrast, the electronic 
distribution played a major role in the production of 50 
antibodies against trichlorophenol.6b To gain some insights 
into the molecular reasons underlying our results, the 
electronic properties of the three haptens were simulated by 
attaching the linkers to the appropriate position of the lowest-
energy PY conformer. As depicted in Figure 4, the 55 
introduction of the spacer arm did not cause a significant 
alteration of the atomic charges, and very close electronic 
similarities between PY and the immunizing haptens were 
found. In hapten PYs5, the hydrocarbon spacer chain is 
tethered to the benzene ring through a sulfur bridge that 60 
replaced the chlorine atom of PY. This substitution meant the 
highest observed modification of the electronic properties 
compared with the two other haptens (the partial charge at C1 
in PYs5 changed by 37%). Nevertheless, this sort of 
replacement, which has been previously used for the design of 65 
haptens for chlorine-containing analytes,16 is less drastic than 
if a C−C bond had been formed. In addition, the antibody with 
the highest affinity to PY was derived from hapten PYs5, so 
electronic charges did not accounted by themselves for the 
observed differences among immunizing haptens.  70 
 
Figure 4 Computed partial atomic charges of PY and haptens PYo5, 
PYa6 and PYs5. Only those atoms showing a charge variation higher 
than 1% between PY and any of the haptens are depicted. Hydrogens 
are not included. 75 
As a further step to understand the reason why hapten 
PYa6 was a poorer mimic of the PY molecule than haptens 
PYo5 and PYs5, the structure of the three synthesized haptens 
was modeled taking into account the flexibility of the spacer 
arm. In order to simplify this analysis, we assumed that in the 80 
synthetic haptens the common PY framework can adopt a 
conformational disposition similar to that of PY itself. A 
preliminary estimation of the preferred orientation of the 
spacer arm in each hapten was done by calculating the 
conformer with the lowest energy in aqueous solution when 85 
the two first C−C bonds of the spacer arm proximal to the 
backbone of the PY molecule were rotated independently 360º 
in 15º increments. From this study, we observed that the 
minimum energy conformers for haptens PYo5 and PYs5 
showed a trend to display the linker away from the backbone 90 
of the molecule. On the contrary, the lowest energy 
conformers of PYa6 showed that the linker has a certain 
tendency to bend over the molecule (Figure 5), a finding that 
provides a feasible explanation for the inferior performance of 
the PYa6 derivative as immunizing hapten.  95 
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Conclusions 
In order to obtain antibodies endowed with appropriate 
binding properties to small organic molecules, optimal 
functionalized derivatives of the target analyte must be 5 
prepared. In the present study, multistep synthetic routes were 
carried out for a better understanding of the importance of the 
derivatization site. Molecular modeling studies indicated that, 
in the case of haptens PYo5 and PYs5, the spacer arm 
facilitated an adequate exposure of the skeleton of PY during 10 
the immune response. On the contrary, the central position of 
the linker in the molecule of PYa6 could have caused steric 
hindrance that impaired the formation of a deep and tight 
binding pocket, typical of most antibody−hapten 
interactions.17 Therefore, interactions between the linker arm 15 
and the backbone of the molecule may occur not only if too 
long spacers are employed, as demonstrated in our previous 
paper,5 but also because of an inappropriate tethering site. 
Acquisition of a larger body of knowledge and more profound 
studies are required in order to better understand the factors 20 
influencing the formation and stabilization of the 
antibody−analyte complex. In practice, these antisera – 
particularly those derived from haptens PYo5 and PYs5 – 
should become very useful reagents for the preparation of 
immunoaffinity columns intended for PY purification and 25 
concentration, as well as for the development of 
immunochemical methods enabling the selective and sensitive 
determination of PY in incurred real samples. 
 
Experimental 30 
PY [methyl {2-[1-(4-chlorophenyl)pyrazol-3-yloxymethyl]-
phenyl}methoxy carbamate] (CAS Registry No. 175013-18-0, 
MW 387.8 g/mol) was purchased, Pestanal grade, from 
Riedel-de-Haën (Seelze, Germany). The methyl 
methoxy(o-tolyl)carbamate (1) used in this work was kindly 35 
provided by BASF AG (Limburgerhof, Germany). tert-Butyl 
hex-5-ynoate (8) and tert-butyl 5-bromopentanoate (15) were 
prepared from commercial hex-5-ynoic acid18 and 5-
bromopentanoic acid, respectively.19 Methyl 
2-(bromomethyl)phenyl(methoxy) carbamate (18) was 40 
prepared from tolylcarbamate 1.20 All melting points were 
determined using a Kofler hot-stage apparatus or a Büchi 
melting point apparatus and are uncorrected. All NMR spectra 
were recorded in CDCl3 or acetone-d6 at rt on a Bruker AC-
300 spectrometer (300.13 MHz for 1H and 75.47 MHz for 45 
13C). The spectra were referenced to residual solvent protons 
in the 1H NMR spectra (7.26 and 2.05 ppm) and to solvent 
carbons in the 13C NMR spectra (77.0 and 30.83 ppm). 
Infrared spectra were measured as thin films between NaCl 
plates for liquid compounds and as KBr pellets for solids 50 
using a Nicolet Avatar 320 spectrometer. Electron-impact (EI) 
and fast atom bombardment (FAB) mass spectra (MS and 
HRMS) were obtained with a Micromass VG Autospec 
spectrometer. ELISA absorbances were read with a 
PowerWave HT microplate reader from BioTek Instruments 55 
(Winooski, VT). A Voyager De-Pro workstation from Applied 
Biosystems was used for the analysis of the molecular weight 
of protein conjugates by matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF-
MS). 60 
Determination of minimum-energy conformations 
The initial generation of low-energy conformations and 
geometry optimizations of PY was made using the 
conformational space search program CONFLEX6 from 
Conflex Corp. (Tokyo, Japan) running on Windows XP. The 65 
visualization and analysis interface BARISTA, a platform 
especially designed for conformational analyses, was used to 
create the initial parameters, and conformation search was 
carried out with MMFF94S (2006-11-24HGTEMP) 
parameters using the default configuration resources, except 70 
for the upper limit value of conformational search that was set 
to cover an area of 10 kcal/mol within the most stable 
conformation (SEL = 10).21 The GBSA continuum solvation 
method was also introduced to evaluate the solvation energy 
contribution to the steric energy.22 The energy distribution of 75 
conformers was established under steric energy analysis. 
Those conformations that were chemically significant 
(accounting for 99.8% of the computed population) were 
grouped based on dihedral angle values (refer to Table 1SI in 
the ESI†) and the lowest-energy conformation of each group 80 
was used to create a potential energy map in which the two 
dihedral angles differing within each group were rotated 
independently 360º in 10º increments using the PM3 
semiempirical method, including the solvent effects of water 
as simulated by the COSMO solvation model. The potential 85 
energy conformation maps were constructed for each selected 
conformation with CAChe WorkSystem Pro from Fujitsu Ltd. 
(Tokyo, Japan) using the MOPAC_OpMap2_PM3_H2O 
procedure. Several of the low-energy conformations obtained 
from each generated potential energy map were chosen and 90 
reoptimized, and the lowest-energy conformations thus 
obtained were selected as the minimum energy conformations 
of PY. Optimized geometries of haptens were also calculated 
using the semi-empirical method PM3 with COSMO water 
simulation using dihedral angle increments of 15º. 95 
Electrostatic potential energy surfaces were mapped over 
electron density isosurfaces using the same force field. The 
Figure 5 Most probable geometries and electron density surfaces colored by electrostatic potential from two different views 
of the three synthesized haptens. Color codes are the same as in Figure 3. 
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electron density probability value used for all calculations was 
0.01 electrons Ǻ-3. 
Buffers and solutions 
The following buffers were employed: PB, 100 mM sodium 
phosphate buffer, pH 7.4; PBS, 10 mM sodium phosphate 5 
buffer, pH 7.4 with 140 mM NaCl; PBST, PBS containing 
0.05% (v/v) Tween 20; CB, 50 mM carbonate−bicarbonate 
buffer, pH 9.6; and washing solution, 150 mM NaCl 
containing 0.05% Tween 20. PY and all other analytes were 
prepared as concentrated solutions in N,N-dimethylformamide 10 
(DMF) and kept at –20 ºC in amber glass vials. 
Hapten synthesis 
The synthesis of hapten PYo5 was previously published.7 
Hapten PYa6 was synthesized from methyl 
methoxy(o-tolyl)carbamate (1)20 following the synthetic route 15 
detailed in Scheme 1 and hapten PYs5 was synthesized from 
commercial methyl (4-iodophenyl)hydrazine (12) following 
the procedure depicted in Scheme 2. Unless otherwise stated, 
organic extracts were successively washed with H2O and 
brine, dried over anhydrous Na2SO4, and concentrated under 20 
vacuum. The characterization data of the synthetic 
intermediates can be found in the ESI†. All solvents were 
purified by distillation and, if required, they were dried 
according to standard methods. 
Synthesis of PYa6 25 
Methyl 4-iodo-2-methylphenyl(methoxy)carbamate (2). 
Ag2SO4 (1.097 g, 3.51 mmol) and I2 (0.893 g, 3.52 mmol) 
were successively added to a solution of methyl 
methoxy(o-tolyl)carbamate (1) (680 mg, 3.48 mmol) in glacial 
acetic acid (9 mL), and the reaction mixture was stirred for 20 30 
h at rt in the dark. After this time, a yellowish precipitate of 
AgI was formed, which was removed by filtration. The filtrate 
and washes were diluted with water and extracted with 
CH2Cl2. The combined organic extracts were successively 
washed with aqueous NaHCO3, aqueous Na2S2O7, brine, and 35 
dried. Evaporation of the solvent under vacuum gave 2 (1.093, 
98%) as a viscous oil that had a purity greater than 95%, as 
judged by 1H NMR analysis, and it was used in the next step 
without further purification. 
Methyl 2-(bromomethyl)-4-iodophenyl(methoxy) 40 
carbamate (3). A solution of methoxycarbamate 2 (810 mg, 
2.50 mmol) and bromine (3.21 g, 1.03 mL, 20.1 mmol, 8 
equiv) in dry CCl4 (90 mL) was irradiated with a mercury 
lamp (125 W) for 36 h at rt. The reaction mixture was washed 
with aqueous Na2S2O7 and brine, and dried. The solvent was 45 
evaporated under vacuum to give an oily residue (885 mg) 
consisting in a mixture of monobrominated compound 3, the 
corresponding dibrominated derivative, and unreacted starting 
material that could not be separated by conventional 
chromatographic purification methods. The percent of 3 in the 50 
mixture was estimated to be 50−55% on the basis of the 
analysis of the mixture by NMR. 
1-(4-Chlorophenyl)-1H-pyrazol-3-ol (6). A solution of 
sodium ethoxyde in ethanol, prepared by dissolving Na (882 
mg, 38.3 mol) in anhydrous ethanol (27 mL), was added to a 55 
suspension of 4-chlorophenylhydrazine hydrochloride (4) 
(3.00 g, 16.75 mmol) in dry toluene (27 mL) stirred under 
nitrogen at 40 ºC. After stirring at the same temperature for 10 
min, methyl acrylate (7.21 g, 7.54 mL, 83.75 mmol) was 
added drop wise during 20 min and the resulting mixture was 60 
stirred for 1.5 h. The reaction mixture was concentrated in a 
rotary evaporator to remove most of the ethanol, then diluted 
with water (300 mL) and extracted with benzene. The benzene 
extracts were extracted with 5% sodium hydroxide and the 
combined aqueous basic phases were acidified with acetic 65 
acid to pH 6 and extracted with benzene. The organic layer 
was washed, dried, and concentrated to give nearly pure 
1-(4-chlorophenyl)pyrazolidin-3-one (5) (2.35 g, 71%) as an 
amorphous solid. 
The above solid (1.265 g, 6.43 mmol) and CuCl (68 mg, 70 
0.32 mmol) were dissolved in DMF (13 mL) and O2 was 
bubbled through the mixture during 3 h at rt. The reaction 
mixture was diluted with H2O (100 mL) and then stirred for 1 
h. The formed precipitate was filtered off, washed with water, 
and dried to afford a brownish solid that was crystallized from 75 
benzene to give 6 (993 mg, 80%) as a slightly colored solid; 
mp 190−192 ºC (from benzene), at 174−176 ºC flake-like 
crystals were transformed into needle like crystals (lit.,10 mp 
181−182 ºC). 
Methyl 2-((1-(4-chlorophenyl)-1H-pyrazol-3-yloxy) 80 
methyl)-4-iodophenyl(methoxy)carbamate (7). A mixture of 
pyrazolol 6 (186.3 mg, 0.96 mmol), benzyl bromide 3 (768 
mg of the mixture obtained above from the bromination of 
methoxycarbamate 2, containing approximately 1.0 mmol of 
3), and CsCO3 (759 mg, 2.32 mmol) in anhydrous DMF (6 85 
mL) was stirred at rt overnight. The reaction mixture was 
diluted with H2O and extracted with ethyl acetate. The organic 
layer was washed and dried. Filtration and evaporation of the 
solvent was followed by column chromatography, using 
hexane−ethyl acetate 8:2 as eluent, to give 7 (395 mg, 80%) as 90 
an oil that solidified upon standing; mp 105−107 ºC (from 
methanol). 
tert-Butyl 6-(3-((1-(4-chlorophenyl)-1H-pyrazol-3-yloxy) 
methyl)-4-(methoxy(methoxycarbonyl)amino)phenyl)hex-5
-ynoate (9). Dry DMF (1.5 mL) and triethylamine (1.2 mL) 95 
were added to a mixture of aryl iodide 7 (241.5 mg, 0.468 
mmol), tert-butyl hex-5-ynoate (8) (117.9 mg, 0.702 mmol), 
Cl2Pd(PPh3)2 (9.3 mg, 1.3 10-2 mmol), and CuI (3.6 mg, 1.9 
10-2 mmol) under nitrogen. The mixture was degassed through 
several freeze−thaw cycles, stirred at rt for 30 min and then at 100 
60 ºC for 4 h. The resulting brownish reaction mixture was 
cooled down, filtered through cotton and most of the 
triethylamine was removed under vacuum. The residue was 
diluted with ethyl acetate and washed, dried, and concentrated. 
Purification by silica gel chromatography, using hexane−ethyl 105 
acetate 9:1 as eluent, afforded compound 9 (255 mg, 98%) as 
an oil. 
tert-Butyl 6-(3-((1-(4-chlorophenyl)-1H-pyrazol-3-yloxy) 
methyl)-4-(methoxy(methoxycarbonyl)amino)phenyl) 
hexanoate (10). A solution of alkyne 9 (243 mg, 0.439 mmol) 110 
and Wilkinson’s catalyst (12.2 mg, 0.013 mmol, 3%) in 
tetrahydrofurane (3 mL) was evacuated and purged under an 
atmosphere of hydrogen gas. Then, the hydrogen pressure was 
regulated to 4 atmospheres and the reaction mixture was 
stirred at rt for 16 h, the solvent was removed under vacuum, 115 
and the residue was purified by chromatography, using 
hexane−ethyl acetate 9:1 as eluent, to furnish compound 10 
(220 mg, 92%). 
6-(3-((1-(4-Chlorophenyl)-1H-pyrazol-3-yloxy)methyl)-4- 
(methoxy(methoxycarbonyl)amino)phenyl)hexanoic acid 120 
(11, hapten PYa6). A solution of the tert-butyl ester 10 (203 
mg, 0.364 mmol) in trifluoroacetic acid (1.5 mL) and CH2Cl2 
(1.5 mL) was stirred at 0 ºC until TLC [developed with 
hexane−ethyl acetate (7:3)] showed completion of the reaction 
(about 1 to 1.5 h). The reaction mixture was concentrated 125 
under vacuum without heating and the residue obtained was 
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purified by silica gel chromatography, using 4% of methanol 
in CHCl3 as eluent, to give the hapten PYa6 (11) (182 mg, 
99%) as a slightly colored viscous oil; δH (CDCl3) 7.70 (1H, 
d, J = 2.6 Hz, H-5 Pz), 7.55 (2H, m, part AA’ of the AA’BB’ 
system, J = 8.8, 2.5, 0.5 Hz, H-2, and H-6 ClPh), 7.47 (1H, d, 5 
J = 1.8 Hz, H-3 Ph), 7.37 (2H, m, part BB’ of the AA’BB’ 
system, J = 8.8, 2.5, 0.5 Hz, H-3, and H-5 ClPh), 7.27 (1H, d, 
J = 8.1 Hz, H-6 Ph), 7.18 (1H, dd, J = 8.1, 1.8 Hz, H-5 Ph), 
5.94 (1H, d, J = 2.6 Hz, H-4 Pz), 5.30 (2H, s, OCH2), 3.79 
(3H, s, CO2CH3), 3.75 (3H, s, NOCH3), 2.66 (2H, t, J = 7.7 10 
Hz, H-6), 2.34 (2H, t, J = 7.4 Hz, H-2), 1.64 (4H, m, H-3 and 
H-5) and 1.40 (2H, m, H-4); δC (CDCl3) 179.01 (C-1), 164.30 
(C-3 Pz), 155.94 (NCO2), 143.46 (C-1 Ph), 138.59 (C-1 
ClPh), 134.92 and 134.40 (C-2 and C-4 Ph), 130.61 (C-4 
ClPh), 129.34 (C-3 and C-5 ClPh), 128.87 and 128.58 (C-3 15 
and C-5 Ph), 127.73 (C-5 Pz), 127.17 (C-6 Ph), 118.93 (C-2 
and C-6 ClPh), 94.33 (C-4 Pz),66.95 (OCH2), 61.94 (NOCH3), 
53.52 (CO2CH3), 35.28 (C-6), 33.80 (C-2), 30.69 (C-5), 28.47 
(C-4) and 24.43 (C-3); υmax/cm-1 (NaCl) 3400-2800, 2933, 
2861, 1735, 1707, 1546, 1501, 1481, 1358, 1094 and 751; m/z 20 
(EI) 441 (8%), 440 (6), 439 (22), 308 (9), 278 (10), 277 (18), 
247 (16), 277 (17), 276 (10), 246 (100) and 194 (59); m/z 
(FAB) calcd for C25H29ClN3O6 (M+ + H) 502.17449, found 
502.17539; λmax (PB)/nm 280 (ε/dm3 mol-1 cm-1 12.1) and 260 
(11.7). 25 
Synthesis of PYs5 
1-(4-Iodophenyl)-1H-pyrazol-3-ol (14). A 1 M solution of 
potassium tert-butoxide in tert-butanol (1.2 mL, 1.2 mmol) 
was added to a solution of (4-iodophenyl)hydrazine (12) (234 
mg, 1 mmol) in anhydrous toluene (1.2 mL) at rt under 30 
nitrogen. The mixture was warmed to 50 ºC and then drop 
wise treated with tert-butyl acrylate (135 mg, 153 µL, 1.05 
mmol). The reaction mixture was stirred at 50 ºC for a few 
minutes, then cooled to rt, diluted with benzene, and extracted 
with 5% aqueous KOH. The aqueous layer was treated with 35 
excess CO2 and the fuchsia solid formed was extracted with 
ethyl acetate (5 times). The combined organic layers were 
washed and dried. Filtration and evaporation of the solvent 
afforded a solid that was crystallized from benzene−acetone to 
give crystals of 1-(4-iodophenyl)pyrazolidin-3-one (13) (179 40 
mg, 62%) as a brown solid; mp 142−143 ºC (from 
benzene−acetone). 
A mixture of the compound 13 obtained above (164 mg, 
0.577 mmol) and CuCl (2.5 mg, 0.03 mmol) in DMF (2.5 mL) 
was stirred in the air until all the starting material was 45 
consumed (about 5 h). The reaction mixture was diluted with 
H2O and the solid formed was collected by filtration, washed 
with cold water, and dried under vacuum to obtain pure 
1-(4-iodophenyl)-1H-pyrazol-3-ol (14) (160 mg, 97%) as a 
cream color solid; needle-like crystals from hexane−ethyl 50 
acetate began to sublimate at 190 ºC and melted at 222−224 
ºC. 
tert-Butyl 5-(4-(3-hydroxy-1H-pyrazol-1-yl)phenylthio) 
pentanoate (17). tert-Butyl 5-mercaptopentanoate (16) was 
prepared from tert-butyl 5-bromopentanoate (15) and thiourea 55 
with very high yield via formation of the thiouronium salt 
followed by cleavage with sodium pyrosulfite.11 Then, a 
mixture of iodophenyl-pyrazolol 14 (200 mg, 0.70 mmol),  
thiol 16 (200 mg, 1.05 mmol), K2CO3 (193 mg, 1.40 mmol), 
CuI (7 mg, 0.035 mmol), and ethylenglycol (78 µL, 1.40 60 
mmol) in 2-propanol (0.7 mL) was degassed through three 
freeze–pump–thaw cycles, sealed under vacuum, and heated at 
80−85 ºC with stirring for 24 h. The cooled reaction mixture 
was diluted with ethyl acetate and washed, dried, and 
concentrated. The brownish oily residue was purified by 65 
column chromatography, using hexane−ethyl acetate mixtures 
from 9:1 to 7:3 as eluent, to give, in order of elution, 
unreacted starting pyrazolol 14 (54 mg, 73% conversion) and 
compound 17 (130 mg, 70%) as a solid; mp 113−114 ºC (from 
hexane−isopropanol). 70 
tert-Butyl 5-(4-(3-(2-(methoxy(methoxycarbonyl)amino) 
benzyloxy)-1H-pyrazol-1-yl)phenylthio)pentanoate (19). A 
mixture of compound 17 (99 mg, 0.284 mmol), methyl 
2-(bromomethyl)phenyl(methoxy)carbamate (18, prepared by 
benzylic bromination of tolylcarbamate 1 with N-75 
bromosuccinimide and azaisobutyronitrile in CCl4 at reflux)8 
(117 mg, 0.427 mmol), and CsCO3 (139 mg, 0.427 mmol) in 
anhydrous DMF (1.2 mL) was stirred at rt overnight under 
nitrogen. The reaction mixture was diluted with ethyl acetate 
and washed, dried, filtered, and then evaporated to dryness. 80 
Purification by column chromatography, using hexane−ethyl 
acetate 9:1 as eluent, afforded compound 19 (134 mg, 89%) as 
a viscous oil. 
5-(4-(3-(2-(Methoxy(methoxycarbonyl)amino)benzyloxy)- 
1H-pyrazol-1-yl)phenylthio)pentanoic acid (20, hapten 85 
PYs5). A solution of the tert-butyl ester 19 (107 mg, 0.197 
mmol) in a 1:1 mixture of trifluoroacetic acid and CH2Cl2 (4 
mL) was stirred at 0 ºC for 1 h. Work-up of the reaction 
mixture as described above for the hydrolysis of 10 to 11, 
followed by chromatography on silica gel and using 90 
CHCl3−methanol 95:5 as eluent, afforded hapten PYs5 (20) 
(86 mg, 90%) as a colorless viscous oil; δH (CDCl3) 7.69 (1H, 
d, J = 2.6 Hz, H-5 Pz), 7.66 (1H, m, H-4 Ph), 7.51 (2H, m, 
part AA’ of the AA’BB’ system, J = 8.8, 2.5, 0.5 Hz, H-2 and 
H-6 SPh), 7.40−7.35 (3H, m, H-3, H-5 and H-6 Ph overlapped 95 
with the part BB’ of the AA’BB’ system corresponding to H-3 
and H-5 SPh), 5.90 (1H, d, J = 2.6 Hz, H-4 Pz), 5.34 (2H, s, 
OCH2), 3.79 (3H, s, CO2CH3), 3.75 (3H, s, NOCH3), 2.91 
(2H, t, J = 7.1 Hz, H-5), 2.36 (2H, t, J = 7.0 Hz, H-2) and 1.72 
(4H, m, H-3 and H-4); δC (CDCl3) 178.86 (C-1), 164.10 (C-3 100 
Pz), 155.84 (NCO2), 138.48 and 137.30 (C-1 and C-2 Ph), 
134.77 (C-1 SPh), 132.69 (C-4 SPh), 130.95 (C-3 and C-5 
SPh), 128.85, 128.80 and 128.48 (C-3, C-4 and C-5 Ph), 
127.66 (C-5 Pz), 127.01 (C-6 Ph), 118.29 (C-2 and C-6 SPh), 
94.05 (C-4 Pz), 66.79 (OCH2), 62.09 (NOCH3), 53.54 105 
(CO2CH3), 33.99 (C-5), 33.35 (C-2), 28.33 (C-4) and 23.58 
(C-3); υmax/cm-1 (NaCl) 3500-2800, 3142, 3044, 2954, 1793, 
1708, 1545, 1480, 1358, 1267, 1100 and 737; m/z (EI) 485 
(M+, 0.1%), 467 (1), 454 (1.5), 453 (4), 437 (6), 425 (7), 424 
(18), 423 (76), 422 (4), 379 (3), 291 (30), 162 (12) and 132 110 
(100); m/z (EI) calcd for C24H27N3O6S 485.16206, found 
485.16249; λmax (PB)/nm 280 (ε/dm3 mol-1 cm-1 19.2) and 260 
(8.15). 
Protein conjugate preparation 
All of the synthesized haptens contained a free carboxylic 115 
group for protein conjugation. The hapten-to-protein MR of 
each bioconjugate was calculated by MALDI-TOF-MS and by 
differential absorbance measurements. For MALDI-TOF-MS 
analysis, a fraction of each conjugate solution was extensively 
dialyzed against pure water at 4 ºC and lyophilized. Samples 120 
were resuspended in acetonitrile−water 7:3 (v/v) containing 
0.1% trifluoroacetic acid, and they were charged into the plate 
in between two layers of sinapinic acid. 
Immunizing conjugates. BSA conjugates were prepared by 
the active ester procedure. Briefly, 20 µmol of hapten in DMF 125 
was mixed with 20 µmol of N-hydroxysuccinimide and 
20 µmol of N,N-dicyclohexylcarbodiimide also in DMF. 
Additional DMF was added to bring the final concentration of 
all reagents to 50 mM. Hapten activation was left to occur 
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overnight at rt in amber vials. The day after, the reaction was 
centrifuged and the supernatant was collected. Next, 200 µL 
of activated hapten solution was added drop wise to 1.0 mL of 
a 15.0 mg/mL BSA solution in CB. The coupling reaction was 
allowed to happen during 4 h at rt with moderate stirring. The 5 
initial hapten-to-protein MR in the reaction mixture was 
approximately 44:1. Finally, the conjugate was separated from 
uncoupled hapten by gel filtration on Sephadex G-25, using 
PB as eluent. The purified bioconjugate was diluted to 1.0 
mg/mL with PB and stored at –20 ºC. For differential 10 
absorbance measurements, the absorbance values of the 
conjugate at 280 and 260 nm were considered. 
Coating conjugates. In this case, the coupling reaction of 
the hapten to the carrier protein was accomplished by the 
mixed anhydride procedure. Basically, 18 µmol of hapten was 15 
dissolved in 180 µL of DMF and mixed with 18 µmol of 
tributylamine and 18 µmol of isobutyl chloroformate also in 
DMF. The concentration of all reagents was brought to 90 
mM with DMF and the hapten was left to be activated during 
1 h at rt. Next, 100 µL of activated hapten solution was added 20 
drop wise to 2.0 mL of a 15.0 mg/mL OVA solution in CB. 
The coupling reaction was carried out during 2.5 h at rt with 
moderate stirring. The initial hapten-to-protein MR in the 
reaction mixture was approximately 13:1. Conjugates were 
processed and stored as described above.  25 
Tracer conjugates. The mixed anhydride method was also 
used to prepare the corresponding enzyme conjugates. First, 
haptens were activated as described above and a 1/10 dilution 
in DMF was prepared after the incubation step. Next, 100 µL 
of this dilution was added drop wise to a 1.0 mL solution of 30 
HRP at 2.2 mg/mL in CB. The coupling reaction was 
incubated for 4 h at rt with moderate stirring. The initial 
hapten-to-protein MR in the reaction mixture was 
approximately 18:1. The tracer was separated from uncoupled 
hapten by gel filtration on Sephadex G-25. For differential 35 
absorbance measurements, the absorbance values of the 
conjugate at 400 and 280 nm were considered in this case. The 
purified tracer was brought to 1.0 mg/mL with PB and diluted 
1:1 (v/v) with PBS containing 1% (w/v) BSA and 0.01% (w/v) 
thimerosal. The conjugate was stored at –20 ºC in amber glass 40 
vials for long-term preservation and a working aliquot was 
kept at 4 ºC. 
Antiserum production 
Animal manipulation was performed in compliance with the 
laws and guidelines of the Spanish Ministry of Science and 45 
Innovation (RD 1201/2005 and law 32/2007) and according to 
the European Directive 2003/65/EC (amending general 
Council Directive 86/609/EEC) concerning the protection of 
animals used for experimental and other scientific purposes. 
Two New Zealand white female rabbits weighing 1–2 kg were 50 
immunized by subcutaneous injection with 0.3 mg of 
conjugate BSA–PYo5, BSA–PYa6, or BSA–PYs5 following 
described procedures.23 For further details see the ESI†. 
Competitive immunoassays 
All antisera were evaluated in the two classical cELISA 55 
formats using both homologous and heterologous conjugates. 
Eight-channel electronic pipettes were employed for rapid and 
precise liquid dispensing. Microplates were washed four times 
with washing solution using a 96-channel ELx405 washer 
from BioTek Instruments (Winooski, VT). After the assay, the 60 
absorbance was read at 492 nm with a reference wavelength at 
650 nm. Sigmoidal curves were mathematically fitted to a 
four-parameter logistic equation using the SigmaPlot software 
package from SPSS Inc. (Chicago, IL). The antiserum titer 
was defined as the reciprocal of the dilution that results in a 65 
maximum absorbance value (Amax) around 1.0 reached at the 
zero dose of analyte when assayed using the indirect 
competitive format with the homologous conjugate at 1.0 
µg/mL. Antibody affinity was estimated as the concentration 
of analyte that reduced 50% (IC50) the Amax value, and the 70 
assay limit of detection was defined as the IC10 of the 
inhibition curve. 
Conjugate-coated indirect assays. ELISA plates were 
coated with 100 µL per well of OVA conjugate solution at 1.0 
and 0.1 µg/mL in CB by overnight incubation at rt. Serial 75 
three-fold antisera dilutions (from 1/1500 to 1/5×105) were 
prepared in PBST. Each plate column received a complete 
standard curve of the analyte in PBS (50 µL per well) 
followed by a given antiserum dilution (50 µL per well). The 
same distribution of the reagents was repeated for each plate 80 
with a different conjugate. The immunological reaction took 
place during 1 h at rt, and plates were washed again as 
described. Next, 100 µL per well of a 1/10000 dilution of goat 
anti-rabbit IgG peroxidase conjugate in PBST was added, and 
plates were incubated 1 h at rt. After washing four times, the 85 
retained peroxidase activity was determined by addition of 
100 µL per well of freshly prepared 2.0 mg/mL of OPD and 
0.012% (v/v) H2O2 in 25 mM citrate and 62 mM sodium 
phosphate buffer, pH 5.4. The enzymatic reaction was stopped 
after 10 min with 100 µL of 2.5 M H2SO4. 90 
Antibody-coated direct assays. Microplates were coated 
with 100 µL per well of a 1/3000, 1/10000, and 1/30000 
dilution of a given antiserum in CB by overnight incubation at 
rt. After four washes, 50 µL per well of PY standard curve 
was dispensed to each plate column and immediately 50 µL 95 
per well of a different concentration of a given enzyme tracer 
was added. In this case, serial three-fold dilutions in PBST of 
the HRP conjugate (from 600 to 2 ng/mL) were prepared. The 
same array of reagent concentrations was distributed in 
another plate that had previously been coated with a different 100 
antiserum. The immunological reaction was carried out during 
1 h at rt and the enzyme activity was revealed as described 
before. 
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